In Nov 2012, Lupin Ltd. had launched its generic version of TriCor. According to IMS Health, TriCor (48 mg and 145 mg) generated US revenues of approximately $1.2 billion for the 12 months ending Mar 31, 2013.

For Indian companies like Cipla, Zydus Cadila, Wockhardt and Dr Reddy's Laboratories Ltd, the percentage of value erosion is expected to be about 9 per cent, while for MNCs like GSK, Ranbaxy, Abboot, Novartis, Sanofi, Pfizer it is likely to be double ...

The combined revenue impact on the top 10 drug makers that control at least 70% of the local market will be about 4.3%, according to an analyst estimate based on a market study by pharma market researcher AIOCD Pharmasofttech AWACS Pvt. Ltd. ... �Scope ...

�A lot will depend on what happens when they start looking through e-mails, texts and IMs, because these companies are talking to other market participants and the circle could widen relatively quickly.

MUMBAI: The national pharma pricing policy will have a limited impact on the industry, leading to a value erosion of just around 2-3% in the over Rs 72,000-crore pharma retail market.

Hyderabad: Dr Reddy's Laboratories Ltd, India's second-biggest drug maker, reported a 67% gain in fourth-quarter profit, beating analyst estimates, on strong generic sales in the US and the settlement of ongoing litigation with a Canadian contract ...

Momenta Pharmaceuticals, Inc. (MNTA) Bank of America Merrill Lynch Health Care Conference Call May 15, 2013 7:20 PM ET. Sumant Kulkarni - Bank of America/Merrill Lynch.

According to the IMS forecasts, the wearable computing market won't gain traction until 2015 because it'll be a bare-bones piece of hardware in the meantime.

Shire ( SHPG ) recently announced that the company settled its pending litigation with Actavis, Inc ( ACT ), formerly known as Watson Pharmaceuticals.

"Control plane applications, such as policy servers, subscriber databases, and IMS, will be among the first virtualized 4G core functions to be implemented in commercial mobile networks," said Gabriel Brown, senior analyst at Heavy Reading. "By ...